Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene therapy, rebisufligene etisparvovec, for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A.
Covered in this story
What has happened since
- Mid-America Apartment Communities is up 1.8% since this was published, 18 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $MAA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Mid-America Apartment Communities →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.